Obesity, Morbid, Periodontal Diseases
Conditions
Keywords
resistin, adiponectin, periodontitis Grading, periodontal therapy
Brief summary
The goal of this clinical trial is to evaluate the relationship between obesity and gingival crevicular fluid resistin and adiponectin in periodontitis patients as well as assess the effect of non-surgical periodontal therapy on their levels using ELISA in obese individuals. Researchers will compare different stages of periodontitis to see if degrees of inflammation and periodontal therapy related obesity
Interventions
PROCEDUREnon-surgical full-mouth periodontal therapy without using adjunct disinfectants
Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
DIAGNOSTIC_TESTGCF level of adiponectin and resistin
Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
Sponsors
Al-Azhar University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* obese persons with Body Mass Index (BMI) more than 40 and suffering from periodontitis
Exclusion criteria
* Patients receiving either antibiotics or non-steroidal anti- inflammatory at least 3 months prior to samples collection. * Patients subjected to previous periodontal therapy 6 months before sampling. Patients with systemic or local inflammatory conditions other than periodontal disease. * Neither lactating nor pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adiponectin level in gingival crevicular fluid | From enrollment to the end of treatment results assessment at 12 weeks |
| resistin level in gingival crevicular fluid | From enrollment to the end of treatment results assessment at 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| clinical attachment level (CAL) | From enrollment to the end of treatment results assessment at 12 weeks |
| probing pocket depth | From enrollment to the end of treatment results assessment at 12 weeks |
| O'Leary Plaque score | From enrollment to the end of treatment results assessment at 12 weeks |
| bleeding on probing percentage (BoP) | From enrollment to the end of treatment results assessment at 12 weeks |
Other
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI) | From enrollment time only |
| glycated hemoglobin (HbA1c) | From enrollment time only |
Countries
Egypt
Outcome results
None listed